Trial · NCT07910773
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
NCT07910773, Not applicable, Recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial. Trials, record NCT07910773. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910773
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
- NCT number
- NCT07910773
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- University of California, San Francisco
- Conditions
- End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
- Interventions
- Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg
- First posted
- 2026-11-02
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of enrolling participants | 4.5 months | The primary feasibility endpoint is the screen-to-enrollment ratio, calculated as the number of participants randomized divided by the number of potentially eligible individuals screened during the recruitment period. Physician refusal and patient refusal rates will also be reported. |
| Secondary | Retention of study participants | 4.5 months | The duration a study participant will be in the study, from the baseline visit. |
| Secondary | Physician adherence to protocol recommendations for achieving target SBP | 4.5 months | |
| Secondary | Patient adherence to home BP measurements and recommended adjustments in dialysis prescription and medications | 4.5 months | Adherence will be assessed by the number of times a patient follows the recommendations across BP measurements, changes in dialysis prescription, and medications. |
| Secondary | SBP achieved in each arm | 4.5 months | |
| Secondary | Change in residual kidney function under two different SBP targets | 4.5 months | Residual kidney function is assessed by 24-hour urine collection as per the dialysis unit protocol and indication. These will be assessed to determine any changes. |
| Secondary | Safety of targeting SBP <120 mmHg vs. <140 mmHg | 4.5 months | |
| Other | Qualitative themes identified from the end-of-study structured participant interviews | 4.5 months | Structured participant interviews will be administered by the study team to the patient to collect qualitative feedback, which will be organized into themes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910773
GET https://conductscience.org/api/trials/v1/NCT07910773/registered